7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis by Miettunen, PM et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Oral presentation
7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in 
pediatric rheumatic diseases associated macrophage activation 
syndrome/reactive hemophagocytic lymphohistiocytosis
PM Miettunen*, A Jayanthan and A Narendran
Address: University of Calgary, Calgary, Canada
* Corresponding author    
Background
Increased interleukin 1 (IL-1) production characterizes
macrophage activation syndrome/reactive hemophago-
cytic lymphohistiocytosis (MAS/rHLH), a potentially
lethal complication of pediatric rheumatic diseases.
Standard treatment (corticosteroids, cyclosporine, +/-
IVIg) is not always effective.
Objective
To test effectiveness of anakinra, a soluble IL-1 receptor
antagonist, in pediatric rheumatology patients who failed
to respond to standard MAS/rHLH therapy.
Methods
6 pediatric rheumatology patients (3 F:3 M); mean
(range) age 8.14 (0.5–13.3) years, with MAS/rHLH were
enrolled (SoJIA n = 4; Churg Strauss vasculitis n = 1; and
infant onset ANCA +ve pulmonary renal syndrome n = 1).
The infant patient was moribund in ICU. Histiocytosis
society's 2004 criteria (HLH2004), including a T-cell acti-
vation marker, soluble IL-2 receptor (sIL2r), were used to
confirm MAS/rHLH. Subcutaneous anakinra (2 mg/kg/
day) was added to existing therapy (high dose IV Methyl-
prednisolone n = 5/6; IVIg n = 6/6, and cyclosporine n =
5/6). HLH2004 specified clinical and laboratory data were
collected pre, 48 hours, and 2 weeks after initiation of
anakinra; including sIL2r in 3/6 patients.
Results
All patients defrevesced within 24 hours of first anakinra
dose, and ventilatory and dialysis support was discontin-
ued within 96 hours in the ICU patient. All patients recov-
ered from MAS/rHLH by 2 weeks; 5/6 pts discontinued
corticosteroids by 5 weeks. Abnormally elevated baseline
sIL2r resolved by 48 hours post first dose of anakinra in all
3 patients tested.
Conclusion
1) Anakinra, in combination with corticosteroids, IVIG, +/
- cyclosporine, was effective in controlling MAS/rHLH in
all patients, allowing rapid discontinuation of corticoster-
oids in 5/6 patients.
2) Elevated baseline sIL2r level normalized rapidly fol-
lowing anakinra, suggesting resolution of abnormal T-cell
activation.
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